Date published: 2025-11-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

HRG-β1 Inhibitors

HRG-β1 inhibitors are a specialized class of compounds that act by modulating the activity of the HRG-β1 protein, which is involved in a variety of cellular signaling processes. These inhibitors typically function by binding to the HRG-β1 protein or its associated receptors, disrupting its interaction with other proteins or ligands necessary for its normal activity. Structurally, HRG-β1 inhibitors can range from small molecules to larger, more complex compounds such as peptides. The design of these inhibitors often incorporates key functional groups that enable strong binding interactions, such as hydrogen bonds, van der Waals forces, and electrostatic interactions with the target protein or receptor. This binding blocks HRG-β1's ability to engage in its usual role in signal transduction, thereby inhibiting downstream biological processes associated with its activity.

From a chemical perspective, HRG-β1 inhibitors are optimized for stability and selectivity. They are often engineered to resist degradation under various conditions, including enzymatic or oxidative breakdown, which ensures that they retain their inhibitory function in different environments. These compounds also exhibit diverse physical properties, such as solubility and permeability, which are important considerations for their effective interaction with the HRG-β1 target in biological systems. Additionally, the kinetics of HRG-β1 inhibitors can vary, with some showing rapid, reversible binding, while others form more prolonged, potentially irreversible interactions with their target. These characteristics are fine-tuned through careful chemical synthesis and structural modification to achieve the desired inhibitory effect, with the ultimate goal of efficiently disrupting HRG-β1 activity at a molecular level.

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Aspirin

50-78-2sc-202471
sc-202471A
5 g
50 g
$20.00
$41.00
4
(1)

Inhibits cyclooxygenase enzymes, potentially affecting inflammation and coagulation pathways.

Warfarin

81-81-2sc-205888
sc-205888A
1 g
10 g
$72.00
$162.00
7
(1)

Inhibits vitamin K-dependent clotting factors, potentially altering coagulation pathways.

Rivaroxaban

366789-02-8sc-208311
2 mg
$155.00
18
(1)

Directly inhibits Factor Xa, possibly affecting coagulation cascade related to HRG-β1's function.

Apixaban

503612-47-3sc-364406
sc-364406A
10 mg
50 mg
$235.00
$622.00
2
(1)

Factor Xa inhibitor, might alter thrombin formation and affect related signaling pathways.

Clopidogrel

113665-84-2sc-507403
1 g
$120.00
1
(0)

Inhibits P2Y12 ADP-receptor on platelets, potentially impacting platelet aggregation and related pathways.

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$25.00
$117.00
$209.00
27
(1)

Tyrosine kinase inhibitor, could affect cell signaling pathways related to cell growth and adhesion.

Sunitinib, Free Base

557795-19-4sc-396319
sc-396319A
500 mg
5 g
$150.00
$920.00
5
(0)

Inhibits multiple receptor tyrosine kinases, potentially affecting angiogenesis and related signaling.

Dexamethasone

50-02-2sc-29059
sc-29059B
sc-29059A
100 mg
1 g
5 g
$76.00
$82.00
$367.00
36
(1)

Glucocorticoid that modulates inflammation, potentially influencing immune response pathways.

Methotrexate

59-05-2sc-3507
sc-3507A
100 mg
500 mg
$92.00
$209.00
33
(5)

Inhibits dihydrofolate reductase, potentially affecting cell proliferation and immune functions.

hydroxychloroquine

118-42-3sc-507426
5 g
$56.00
1
(0)

Modulates immune activity, possibly affecting pathways related to inflammation and autoimmunity.